[A19-52] Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2019
Project no.:
A19-52
Commission:
Commission awarded on 18.06.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with type 2 diabetes mellitus
Added benefit not proven for any of the 3 subindications specified by the G-BA because the drug manufacturer did not address these research questions in its dossier
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-93 | Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52 | Commission completed |
| A17-66 | Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A14-07 | Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2019-12-19 A G-BA decision was published.